EBS
Price
$6.40
Change
-$0.10 (-1.54%)
Updated
May 23 closing price
Capitalization
120.07M
79 days until earnings call
SIGA
Price
$5.91
Change
+$0.07 (+1.20%)
Updated
May 23 closing price
Capitalization
608.54M
67 days until earnings call
Interact to see
Advertisement

EBS vs SIGA

Header iconEBS vs SIGA Comparison
Open Charts EBS vs SIGABanner chart's image
Emergent Biosolutions
Price$6.40
Change-$0.10 (-1.54%)
Volume$1.18M
Capitalization120.07M
SIGA Technologies
Price$5.91
Change+$0.07 (+1.20%)
Volume$479.59K
Capitalization608.54M
EBS vs SIGA Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIGA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. SIGA commentary
May 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and SIGA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 25, 2025
Stock price -- (EBS: $6.40 vs. SIGA: $5.91)
Brand notoriety: EBS and SIGA are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 93% vs. SIGA: 91%
Market capitalization -- EBS: $120.07M vs. SIGA: $608.54M
EBS [@Pharmaceuticals: Other] is valued at $120.07M. SIGA’s [@Pharmaceuticals: Other] market capitalization is $608.54M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileSIGA’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • SIGA’s FA Score: 2 green, 3 red.
According to our system of comparison, SIGA is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 5 TA indicator(s) are bullish while SIGA’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 5 bullish, 4 bearish.
  • SIGA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both EBS and SIGA are a good buy in the short-term.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а -3.61% price change this week, while SIGA (@Pharmaceuticals: Other) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.77%. For the same industry, the average monthly price growth was +10.77%, and the average quarterly price growth was +40.56%.

Reported Earning Dates

EBS is expected to report earnings on Aug 12, 2025.

SIGA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.77% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SIGA($609M) has a higher market cap than EBS($120M). EBS has higher P/E ratio than SIGA: EBS (17.73) vs SIGA (9.24). SIGA YTD gains are higher at: 8.597 vs. EBS (-33.054). SIGA has higher annual earnings (EBITDA): 84.2M vs. EBS (-518.2M). SIGA has more cash in the bank: 150M vs. EBS (112M). SIGA has less debt than EBS: SIGA (564K) vs EBS (860M). EBS has higher revenues than SIGA: EBS (1.02B) vs SIGA (140M).
EBSSIGAEBS / SIGA
Capitalization120M609M20%
EBITDA-518.2M84.2M-615%
Gain YTD-33.0548.597-384%
P/E Ratio17.739.24192%
Revenue1.02B140M731%
Total Cash112M150M75%
Total Debt860M564K152,482%
FUNDAMENTALS RATINGS
EBS vs SIGA: Fundamental Ratings
EBS
SIGA
OUTLOOK RATING
1..100
3326
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
9438
PRICE GROWTH RATING
1..100
4851
P/E GROWTH RATING
1..100
1020
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (1) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (56) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than EBS’s over the last 12 months.

SIGA's Profit vs Risk Rating (87) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that SIGA’s stock grew similarly to EBS’s over the last 12 months.

SIGA's SMR Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (94) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than EBS’s over the last 12 months.

EBS's Price Growth Rating (48) in the Biotechnology industry is in the same range as SIGA (51) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SIGA’s over the last 12 months.

EBS's P/E Growth Rating (10) in the Biotechnology industry is in the same range as SIGA (20) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SIGA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSSIGA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIGA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSRPF0.080.01
+8.77%
Novo Resources Corp
SSMXY16.890.09
+0.54%
Sysmex Corp.
RWEOY36.990.09
+0.24%
RWE AG
BTLCY5.18-0.02
-0.35%
British Land Company (The) PLC
HESAF2690.00-10.00
-0.37%
Hermes International SA